Biotech executive brings global leadership and operations experience to speed clinical development, expand operations, and ...
Baylor Genetics, a leading diagnostic genomics partner offering a full spectrum of comprehensive genetic tests and diagnostic ...
Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage global ...
The CellShield product line is DMSO-free and includes a controlled rate freezing program that optimizes viability, recovery ...
"As the first ENPP1 inhibitor in the clinic, RBS2418 is bringing a new type of immunotherapy to the field. Seeing immune ...
AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a ...
Silence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight ...
Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and ...
The European Commission approved Germany’s financial support after assessing the risks of Sanofi stopping insulin API ...
NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary ...
Conference call and webcast to take place on Friday, October 23, 2026, at 8:00 a.m. ET. Event to feature Dr. Joshua Sabari to ...
October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results